Literature DB >> 19011234

Psychiatric comorbidities and schizophrenia.

Peter F Buckley1, Brian J Miller, Douglas S Lehrer, David J Castle.   

Abstract

Psychiatric comorbidities are common among patients with schizophrenia. Substance abuse comorbidity predominates. Anxiety and depressive symptoms are also very common throughout the course of illness, with an estimated prevalence of 15% for panic disorder, 29% for posttraumatic stress disorder, and 23% for obsessive-compulsive disorder. It is estimated that comorbid depression occurs in 50% of patients, and perhaps (conservatively) 47% of patients also have a lifetime diagnosis of comorbid substance abuse. This article chronicles these associations, examining whether these comorbidities are "more than chance" and might represent (distinct) phenotypes of schizophrenia. Among the anxiety disorders, the evidence at present is most abundant for an association with obsessive-compulsive disorder. Additional studies in newly diagnosed antipsychotic-naive patients and their first-degree relatives and searches for genetic and environmental risk factors are needed to replicate preliminary findings and further investigate these associations.

Entities:  

Mesh:

Year:  2008        PMID: 19011234      PMCID: PMC2659306          DOI: 10.1093/schbul/sbn135

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  189 in total

1.  Lifetime prevalence of mood and anxiety disorders in twin pairs discordant for schizophrenia.

Authors:  M J Lyons; J Huppert; R Toomey; R Harley; J Goldberg; S Eisen; W True; S V Faraone; M T Tsuang
Journal:  Twin Res       Date:  2000-03

2.  A follow-up and family study of schizophrenia.

Authors:  S B Guze; C R Cloninger; R L Martin; P J Clayton
Journal:  Arch Gen Psychiatry       Date:  1983-12

3.  Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness.

Authors:  Peter F Buckley
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

4.  Anxiety and substance use comorbidity among inpatients with schizophrenia.

Authors:  Renee D Goodwin; Xavier F Amador; Dolores Malaspina; Scott A Yale; Raymond R Goetz; Jack M Gorman
Journal:  Schizophr Res       Date:  2003-05-01       Impact factor: 4.939

5.  The validity of major depression with psychotic features based on a community study.

Authors:  J Johnson; E Horwath; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1991-12

Review 6.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

7.  Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich.

Authors:  B Bandelow; P Müller; W Gaebel; W Köpcke; M Linden; F Müller-Spahn; A Pietzcker; F M Reischies; J Tegeler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

8.  Schizophrenia: lifetime co-morbidity in a community sample.

Authors:  R C Bland; S C Newman; H Orn
Journal:  Acta Psychiatr Scand       Date:  1987-04       Impact factor: 6.392

9.  The prognostic significance of obsessive-compulsive symptoms in schizophrenia.

Authors:  W S Fenton; T H McGlashan
Journal:  Am J Psychiatry       Date:  1986-04       Impact factor: 18.112

10.  Neurocognitive deterioration in elderly chronic schizophrenia patients with and without PTSD.

Authors:  Craig Goodman; Boris Finkel; Mahmud Naser; Piter Andreyev; Yehoshua Segev; Rena Kurs; Yuval Melamed; Avi Bleich
Journal:  J Nerv Ment Dis       Date:  2007-05       Impact factor: 2.254

View more
  252 in total

1.  Cross-Disorder Cognitive Impairments in Youth Referred for Neuropsychiatric Evaluation.

Authors:  Alysa E Doyle; Pieter J Vuijk; Nathan D Doty; Lauren M McGrath; Brian L Willoughby; Ellen H O'Donnell; H Kent Wilson; Mary K Colvin; Deanna C Toner; Kelsey E Hudson; Jessica E Blais; Hillary L Ditmars; Stephen V Faraone; Larry J Seidman; Ellen B Braaten
Journal:  J Int Neuropsychol Soc       Date:  2017-08-04       Impact factor: 2.892

Review 2.  Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction.

Authors:  Jody Mayfield; Yuri A Blednov; R Adron Harris
Journal:  Int Rev Neurobiol       Date:  2015-06-22       Impact factor: 3.230

3.  [Schizophrenia spectrum disorders in elderly patients : Analysis of reasons for admission to a department of geriatric psychiatry].

Authors:  C Jagsch; G Dietmaier; M Jagsch; R E Roller
Journal:  Z Gerontol Geriatr       Date:  2016-07-19       Impact factor: 1.281

4.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2015-02-27       Impact factor: 7.853

5.  Prediction of Schizophrenia Diagnosis by Integration of Genetically Correlated Conditions and Traits.

Authors:  Jingchun Chen; Jian-Shing Wu; Travis Mize; Dandan Shui; Xiangning Chen
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-01       Impact factor: 4.147

6.  Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence.

Authors:  Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

Review 7.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

Review 8.  Implications of germline copy-number variations in psychiatric disorders: review of large-scale genetic studies.

Authors:  Masahiro Nakatochi; Itaru Kushima; Norio Ozaki
Journal:  J Hum Genet       Date:  2020-09-21       Impact factor: 3.172

9.  Obsessive compulsive symptoms in individuals at clinical risk for psychosis: association with depressive symptoms and suicidal ideation.

Authors:  Jordan E DeVylder; Amy J Oh; Shelly Ben-David; Neyra Azimov; Jill M Harkavy-Friedman; Cheryl M Corcoran
Journal:  Schizophr Res       Date:  2012-07-28       Impact factor: 4.939

Review 10.  Anxiety as a core aspect of schizophrenia.

Authors:  Stefano Pallanti; Andrea Cantisani; Giacomo Grassi
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.